Expanding Drug Development Across APAC: Opportunities, Challenges, & the Path to Japan
Monday, November 9th | 11:00 AM
MassBioHub | Cambridge, MA
As global drug development becomes increasingly competitive, with Asia representing 43% of total global developmental assets, sponsors are looking beyond traditional markets to accelerate clinical development, access diverse patient populations, and build strategies that support access to important markets worldwide.
Join CMIC and MassBio for an in-person lunch and learn exploring the opportunities and challenges of incorporating South Korea, Taiwan, Japan, and other key APAC markets into global clinical development programs.
Experts will share practical insights on navigating the regulatory and operational differences across APAC, selecting the right countries and sites, and integrating Japan into a broader global development strategy. The discussion will also cover patient recruitment and site strategies in competitive therapeutic areas like oncology, with lessons applicable to clinical development across APAC.
Through expert discussion and real-world examples, attendees will gain practical insights into:
- Incorporating APAC into global study programs
- Regulatory and operational considerations across APAC
- Oncology recruitment and site strategies
- Early considerations for bringing innovative therapies to the Japan market
- Case studies from global biotech sponsors expanding into Asia
Whether you’re planning first-in-human studies, expanding a late-stage global program, or evaluating Japan as a future market, this discussion will provide practical guidance for building an integrated development strategy across APAC.
Register for the lunch and learn here: https://en.cmicgroup.com/massbio-lunch-and-learn-november-9-2026-event-registration/
- Please note: Submitting the form does not guarantee admission. Due to limited capacity, your registration will be confirmed only after you receive a confirmation email with your official event ticket.
